Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Mayne Pharma Group ( (AU:MYX) ) is now available.
UBS Group AG and its related bodies corporate have reduced their voting power in Mayne Pharma Group Limited from 7.26% to 5.77% as of May 23, 2025. This change in substantial holding reflects a shift in UBS’s investment strategy, potentially impacting Mayne Pharma’s shareholder dynamics and market perception.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$7.09 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Average Trading Volume: 914,334
Technical Sentiment Signal: Sell
Current Market Cap: A$391.6M
For an in-depth examination of MYX stock, go to TipRanks’ Stock Analysis page.